试验终止ClinicalTrials.gov(美国登记平台)来源日期:2024-08-06
A Study of RBI-4000 in Healthy Participants
编号:NCT06048770登记状态:提前终止企业 / 申办者:Replicate Bioscience
药物 / 成分:RBI-4000、RabAvert
登记的停止原因(原文):Strategic business decision (not related to safety, efficacy, or quality)
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2024-08-06
TQB2928 Injection Combined With Penpulimab in Treatment of Advanced Malignant Tumors.
编号:NCT06297642登记状态:提前终止企业 / 申办者:Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
药物 / 成分:TQB2928 injection、Penpulimab
登记的停止原因(原文):Based on the current status of the same target research and the company's overall layout in the field of tumors, the early termination was determined after full communication with the principal investigator of the group leader unit.
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2024-08-05
QUILT-3.090: NANT Squamous Cell Carcinoma (SCC) Vaccine: Subjects With SCC Who Have Progressed
编号:NCT03387111登记状态:提前终止企业 / 申办者:ImmunityBio, Inc.
药物 / 成分:Aldoxorubicin HCl、ETBX-011、ETBX-021、ETBX-051
登记的停止原因(原文):Study halted prematurely and will not resume; participants are no longer being examined or receiving intervention
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2024-08-05
Prospective, Randomized, Double-Blind, Placebo-Controlled, Crossover Study in Symptomatic CD Patients
编号:NCT04243551登记状态:提前终止企业 / 申办者:Entero Therapeutics
药物 / 成分:Latiglutenase、Placebo
登记的停止原因(原文):Due to low enrollment related to Covid.
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2024-08-05
Study of Latiglutenase in T1D/CD Patients
编号:NCT04839575登记状态:提前终止企业 / 申办者:Entero Therapeutics
药物 / 成分:Latiglutenase、Placebo
登记的停止原因(原文):Covid-19 interruptions and enrollment challenges
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2024-08-02
Dose-finding Study Using Pentostatin for Injection in the Treatment of Steroid-refractory aGvHD
编号:NCT00032773登记状态:提前终止企业 / 申办者:Astex Pharmaceuticals, Inc.
药物 / 成分:pentostatin for injection
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2024-08-02
Orathecin + Gemcitabine Versus Placebo + Gemcitabine in Chemonaive Non-Resectable Pancreatic Cancer
编号:NCT00113256登记状态:提前终止企业 / 申办者:Astex Pharmaceuticals, Inc.
药物 / 成分:Rubitecan
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2024-08-02
Study to Assess the Safety of Escalating Doses of AT9283, in Patients With Leukemias
编号:NCT00522990登记状态:提前终止企业 / 申办者:Astex Pharmaceuticals, Inc.
药物 / 成分:AT9283
登记的停止原因(原文):Recommended Phase II dose determined
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2024-08-02
Safety of SGI-1776, A PIM Kinase Inhibitor in Refractory Prostate Cancer and Relapsed/Refractory Non Hodgkin's Lymphoma
编号:NCT00848601登记状态:提前终止企业 / 申办者:Astex Pharmaceuticals, Inc.
药物 / 成分:SGI-1776
登记的停止原因(原文):The dose limiting toxicity of cardiac QTc prolongation was identifiedin the phase 1 study in patients with refractory prostate and lymphoma
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2024-08-02
Biofreeze® vs. a Placebo on Knee Osteoarthritis Walking Gait Characteristics and Pain
编号:NCT03888807登记状态:提前终止企业 / 申办者:Sport and Spine Rehab Clinical Research Foundation
药物 / 成分:Biofreeze、Placebo
登记的停止原因(原文):Decided not go move forward with this population as recruitment was difficult
查看官方原始记录 ↗